Drug Profile
Research programme: glaucoma gene therapy - Quethera
Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator University of Cambridge
- Developer Quethera
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Glaucoma in United Kingdom (Intraocular, Injection)
- 10 Dec 2020 The glaucoma gene therapy programme is still in preclinical development
- 10 Dec 2020 Astellas Pharma plans to submit an IND application for Glaucoma, in 2023